We are live on ! Find out more
SGYP

Synergy Pharmaceuticals
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

72 hedge funds and large institutions have $139M invested in Synergy Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

260% more call options, than puts

Call options by funds: $824K | Put options by funds: $229K

4% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 24

1.68% less ownership

Funds ownership: 28.1% → 26.42% (-1.7%)

6% less funds holding

Funds holding: 77 → 72 (-5)

25% less capital inflows, than outflows

Capital inflows: $8.45M | Capital outflows: $11.3M

29% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 17

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
72
Holders Change
-5
Holders Change %
-6.49%
% of All Funds
2.08%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
12
Increased
25
Reduced
24
Closed
17
Calls
$824​K
Puts
$229​K
Net Calls
+$595​K
Net Calls Change
+$421​K

SGYP Hedge Fund Activity: Q4 2013 in Review

72 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals (SGYP) for Q4 2013, worth a combined $139M — up 20% from $116M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of SGYP and 12 opened new positions — a net loss of 5 holders — while 24 trimmed existing stakes and 25 added.

The largest buyer was Oxford Asset Management, opening a new position worth an estimated $2.1M. The largest seller was Fidelity Investments, cutting an estimated $3.5M.

  • 72 institutional investors held Synergy Pharmaceuticals (SGYP) as of Q4 2013, down from 77 in Q3 2013.
  • Funds reported $139M of Synergy Pharmaceuticals stock for Q4 2013, up 20% quarter-over-quarter.
  • 12 funds opened new Synergy Pharmaceuticals positions in Q4 2013 and 17 closed out, a net change of -5 holders.
  • The largest Synergy Pharmaceuticals buyer in Q4 2013 was Oxford Asset Management, an estimated $2.1M added.
  • The largest Synergy Pharmaceuticals seller in Q4 2013 was Fidelity Investments, an estimated $3.5M sold.

Based on aggregated 13F filings for Q4 2013.